Pharmaceutical giant Novavax is developing a two-in-one COVID/flu vaccine.

According to the company’s Chief Medical Officer, Filip Dubovsky, the two-in-one vaccine combines 25 micrograms of COVID vaccine and 35 micrograms of flu vaccine.

“What we demonstrated in this study is we were able to get the immune responses really comparable to what the individual vaccines did prior to combination,” Dubovsky said.

He continued, saying, “Combination vaccines are an attractive public health intervention. You are hitting two life-threatening diseases in one medical contact, giving a single vaccination.”

It’s curious that Novavax, which has not had its COVID vaccine authorized by the FDA like other big pharma companies, thinks it’s good to combine two vaccines for two different viruses when mixing two different COVID-19 vaccines is rejected by several countries.

“COVID-19 vaccines are not interchangeable,” Centers for Disease Control (CDC) spokesperson Jasmine Reed said in 2021. “The safety and effectiveness of receiving two different COVID-19 vaccines has not been studied.”

It should also be noted that, unlike Pfizer and Moderna, Novavax is not utilizing experimental mRNA technology to develop their latest vaccine nor their COVID-exclusive vaccine.

Instead, the virus spike is synthesized outside the body, put inside a baculovirus that infects insect cells to create copies of the spike, which are subsequently purified and extracted, reports CNBC.

Pfizer and Moderna are also working on a flu vaccine, though it isn’t clear the companies intend to merge it with their COVID vaccine.

In fact, Pfizer and Moderna are both in a race to produce mRNA vaccines for just about everything, including heart attacks, therapeutics for diabetes, cancer vaccines, and HIV vaccines.